FDAFDA recall D-0076-2027 · Oct 28, 2026
Hikma Pharmaceuticals USA INC.: Abirtega (abiraterone acetate) USP recall
Quick answer
- Product
- Abirtega (abiraterone acetate) USP, 250 mg, 120-count bottles, Rx only, Rx only, Mfd for: Hikma Pharmaceuticals USA Inc., Berkley Heights, NJ 07922 USA by: Arab Pharmaceuticals Manufacturing PSC PO Box 41, Sahab-Jordon, NDC 82249-011-12.
- Brand
- Hikma Pharmaceuticals USA INC.
- Codes, lots and dates
- Lot #: 3047, Exp Date July 2027.
- Hazard
- Failed Tablet/Capsule Specifications: Failed tablet specifications for weight uniformity.
- Distribution
- Nationwide within the United States
- Quantity
- 2136 bottles
- Recall date
- Oct 28, 2026
- Agency
- U.S. Food and Drug Administration (FDA) enforcement report
- Recall number
- D-0076-2027
Recall found
Product
Abirtega (abiraterone acetate) USP, 250 mg, 120-count bottles, Rx only, Rx only, Mfd for: Hikma Pharmaceuticals USA Inc., Berkley Heights, NJ 07922 USA by: Arab Pharmaceuticals Manufacturing PSC PO Box 41, Sahab-Jordon, NDC 82249-011-12.
Reason for recall
Failed Tablet/Capsule Specifications: Failed tablet specifications for weight uniformity.
What to do
FDA enforcement reports don't include consumer instructions. Check the codes below against your packaging. If this is a medicine or device you use, talk to your pharmacist or doctor before you stop or change anything, and contact the company or FDA for what to do with the product.
| Quantity | 2136 bottles |
|---|---|
| Codes, lots and dates | Lot #: 3047, Exp Date July 2027. |
| Distribution | Nationwide within the United States |
| Recall date | Oct 28, 2026 |
| Class | Class II |
| Agency ID | D-0076-2027 |
| Official notice | U.S. Food and Drug Administration (FDA) enforcement report |
| Data as of, last checked | Nov 21, 2026, 3:48 PM EST |
Recall details
- FDA classification
- Class II: use of or exposure to the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
- Status
- Ongoing
- Codes, lots and dates
- Lot #: 3047, Exp Date July 2027.
- Quantity
- 2136 bottles
- Distribution
- Nationwide within the United States
- Recalling firm
- Hikma Pharmaceuticals USA INC., Columbus, OH
- Voluntary or mandated
- Voluntary: Firm initiated
- Recall started
- 2026-10-06
Source: openFDA enforcement record D-0076-2027 · search recall number D-0076-2027 in FDA's Enforcement Report.
Copied from the agency record without changes. Data as of Nov 21, 2026, 3:48 PM EST. The agency notice is the final word.
FAQ
What was recalled?
Product: Abirtega (abiraterone acetate) USP, 250 mg, 120-count bottles, Rx only, Rx only, Mfd for: Hikma Pharmaceuticals USA Inc., Berkley Heights, NJ 07922 USA by: Arab Pharmaceuticals Manufacturing PSC PO Box 41, Sahab-Jordon, NDC 82249-011-12. Brand: Hikma Pharmaceuticals USA INC. Codes, lots and dates: Lot #: 3047, Exp Date July 2027.
What is the hazard?
Failed Tablet/Capsule Specifications: Failed tablet specifications for weight uniformity.
How do I check if mine is affected?
Codes, lots and dates: Lot #: 3047, Exp Date July 2027.
Where was it distributed?
Nationwide within the United States
Related recalls
- Hikma Pharmaceuticals USA INC.: Ciprofloxacin Tablets recall
- Hikma Pharmaceuticals USA INC.: Ciprofloxacin Tablets recall
- Hikma Pharmaceuticals USA INC.: Ramipril Capsules USP recall
- Greenwich: Compounded sterile products
- Breckenridge Pharmaceutical, Inc.: Propranolol Hydrochloride Extended-Release Capsules, USP, 60mg
- React Health dba 3B Medical, Inc.: Bilevel Positive Airway Pressure (BPAP) System
